Compare ABX & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ABX | CBLL |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | 326 | 280 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 750.1M |
| IPO Year | N/A | N/A |
| Metric | ABX | CBLL |
|---|---|---|
| Price | $8.25 | $17.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.50 | ★ $23.20 |
| AVG Volume (30 Days) | ★ 500.2K | 311.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.18 | $29.57 |
| Revenue Next Year | $14.60 | $28.44 |
| P/E Ratio | $74.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.18 | $10.85 |
| 52 Week High | $10.54 | $24.33 |
| Indicator | ABX | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 35.43 | 37.23 |
| Support Level | $7.25 | $15.84 |
| Resistance Level | $9.71 | $19.67 |
| Average True Range (ATR) | 0.40 | 0.74 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 0.68 | 25.13 |
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The company operates through four distinct yet complementary divisions: Abacus Life Solutions, Abacus Asset Group, Abacus Intel, and Abacus Wealth Advisors. It operates through three reportable segments, Asset management, Life solutions, and Technology services. It derives the majority revenue from Life solutions segment that generates revenues by buying, selling, and trading policies, and maintaining policies until receipt of death benefits. It also generates revenue by originating life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.